Compare
Mustang Bio, Inc. vs Lisata Therapeutics, Inc. vs Impact Biomedical Inc. vs Clene Inc.
| Latest fiscal year | Mustang Bio, Inc. MBIO | Lisata Therapeutics, Inc. LSTA | Impact Biomedical Inc. IBO | Clene Inc. CLNN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $170.0K | $32.0K | $200.0K |
| Revenue growth (YoY) | n/a | -83.0% | n/a | -41.5% |
| Gross margin | n/a | n/a | n/m (computed) | 78.5% (computed) |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/a | n/m | n/m | n/m |
| Net income | -$1.92M | -$16.59M | -$11.84M | -$26.17M |
| EPS (Diluted) | -$0.39 | -$1.91 | -$0.38 | n/a |
| Operating cash flow | -$5.26M | -$15.95M | -$1.89M | -$18.55M |
| Free cash flow | n/a | -$15.98M | n/a | -$18.59M |
| Cash & equivalents | $17.27M | $15.96M | $3.0K | $5.19M |
| Total assets | $17.59M | $17.74M | $17.41M | $18.13M |
| Total liabilities | $8.06M | $3.14M | $1.85M | $35.72M |
| Shareholders' equity | $9.53M | $14.86M | $12.61M | -$17.59M |
| Return on year-end equity | -20.2% | -111.7% | -93.9% | n/a |
| Shares outstanding | n/a | 8.83M | 104.62M | 10.85M |
Revenue, most recent five fiscal years
| Fiscal year | Mustang Bio, Inc. | Lisata Therapeutics, Inc. | Impact Biomedical Inc. | Clene Inc. |
|---|---|---|---|---|
| Latest | n/a | $170.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $200.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $1.00M Ended 2024-12-31 | n/a | $342.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | $654.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $50.0K Ended 2022-12-31 | $473.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $723.0K Ended 2021-12-31 |